Download PDF
Thromb Haemost 1985; 53(03): 303-305
DOI: 10.1055/s-0038-1661302
Original Article
Schattauer GmbH Stuttgart

The Effect of the Synthetic Steroid ORG OD14 on Fibrinolysis and Blood Lipids in Postmenopausal Women

Isobel D Walker
1   The Department of Haematology, Royal Infirmary, Glasgow, UK
,
J F Davidson
1   The Department of Haematology, Royal Infirmary, Glasgow, UK
,
A Richards
2   The Department of Gynaecology, Royal Infirmary, Glasgow, UK
,
R Yates
2   The Department of Gynaecology, Royal Infirmary, Glasgow, UK
,
H P McEwan
2   The Department of Gynaecology, Royal Infirmary, Glasgow, UK
› Author Affiliations
Further Information

Publication History

Received 01 June 1984

Accepted 07 February 1985

Publication Date:
18 July 2018 (online)

  PDF Download  Permissions and Reprints

Summary

Two groups of postmenopausal women were compared. One group of 13 was given the synthetic steroid Org OD14 to suppress climacteric symptoms and one group of 14 was given placebo. After a 2 week baseline period the subjects received daily for 12 weeks, either 2.5 mg Org OD14 or placebo. There were no significant differences between the groups pre-treatment. Compared with the placebo group, during treatment, the Org OD14 group showed the following significant differences: higher haemoglobin, haematocrit, platelet count, plasminogen, fibrinolytic activity on fibrin plates and antithrombin III and lower fibrinogen. No significant differences between the groups were found in α2 antiplasmin levels, total cholesterol, total triglycerides, bilirubin or transaminase levels but the Org OD14 group had significantly lower levels of HDL cholesterol. With the exception of the haemoglobin and haematocrit levels all of the differences had disappeared by 2 weeks post treatment.

Keywords

Synthetic steroid - Anabolic steroid effect - Fibrinolysis - Blood lipids - Antithrombin III - Plasminogen - Fibrinogen
 

  • References

  • 1 Lindsay R, Hart DM, Kraszewski A. Prospective double-blind trial of synthetic steroid (Org OD14) for preventing post-menopausal osteoporosis. Br Med J 1980; 1: 1207-1209
    PubMedGoogle Scholar
  • 2 Kicovic PM, Cortes-Prieto J, Luis M, Milojevic S, Franchi F. Placebo controlled cross-over study of effects of Org OD14 in menopausal women. Reproduccion 1982; 6: 81-91
    PubMedGoogle Scholar
  • 3 Lowe GD O, Forbes CD. Anabolic steroids and the fibrinolytic defence system against thrombosis. Scott Med J 1981; Supplement 1-104
    PubMedGoogle Scholar
  • 4 Small M, McArdle BM, Lowe GD O, Forbes CD, Prentice CR M. The effect of intramuscular stanozolol on fibrinolysis and blood lipids. Thromb Res 1982; 28: 27-36
    CrossrefPubMedGoogle Scholar
  • 5 Dacie JV, Lewis SM, Pitney WR. Investigations of haemorrhagic disorders. In practical Haematology. Dacie JV, Lewis SM. (Eds) 5. pp 314-403 Churchill Livingstone; Edinburgh: 1975
    Google Scholar
  • 6 Clauss A. Gerinnungsphysiologische Schnellmethode zur Bestimmung des Fibrinogens. Acta Haematol 1957; 17: 237-246
    CrossrefPubMedGoogle Scholar
  • 7 Friberger P. Chromogenic peptide substrates. Their use for assay of factors in the fibrinolytic and the plasma kallikrein-kinin systems Scand J Clin Lab Invest 1982; 42 Suppl (Suppl. 162) 41-54
    PubMedGoogle Scholar
  • 8 Abildgaard U, Lie M, Odegard OR. Antithrombin (heparin co-factor) assay with new chromogenic substrates (S-2238 and Chromozym TH). Thromb Res 1977; 11: 549-553
    CrossrefPubMedGoogle Scholar
  • 9 Kluft C, Brakman P, Veldhuyzen-Stolk EC. Screening of fibrinolytic activity in plasma euglobulin fractions on the fibrin plate. In Progress in Chemical Fibrinolysis and Thrombolysis. Davidson JF, Samama MM, Desnoyers PC. (Eds) Raven Press; New York: 1976. II 57-65
    Google Scholar
  • 10 Preston FE, Burakowski BK, Porters NR, Malia RG. The fibrinolytic response to stanozolol in normal subjects. Thromb Res 1981; 22: 543-551
    CrossrefPubMedGoogle Scholar
  • 11 Preston FE, Malia RG, Greaves M, Wijngaards. Kluft C. The effect of stanozolol on thrombotic risk factors in healthy individuals. In Progress in Fibrinolysis. Davidson JF, Bachmann F, Bouvier CA, Kruithof EK O. (Eds) Churchill Livingstone; Edinburgh: 1983. Vol.VI: p 518-522
    Google Scholar
  • 12 Ogston CM, Ogston D. Plasma fibrinogen and plasminogen levels in health and in ischaemic heart disease. J Clin Pathol 1966; 19: 352-356
    CrossrefPubMedGoogle Scholar
  • 13 Lowe GD O, McArdle BM, Stromberg P, Lorimer AR, Forbes CD, Prentice CR. Increased blood viscosity and fibrinolytic inhibitor in type II hyperlipo- proteinaemia. Lancet 1982; 1: 472-475
    PubMedGoogle Scholar
  • 14 Kluft C, Preston FE, Malia RG, Wijngaards G. Characterisation of the effect of stanozolol on fibrinolytic parameters in healthy volunteers. In Progress in Fibrinolysis. Davidson JF, Nilsson IM, Astedt B. (Eds) Churchill Livingstone; Edinburgh: 1983. Volume VI 513-518
    Google Scholar
  • 15 Taggart H, Haffner S, Chestnut C, Albers J, Hazzard W. An anabolic steroid (stanozolol) markedly reduces high density lipoproteins in post menopausal women. Arteriosclerosis 1981; 1: 92-93
    PubMedGoogle Scholar
  • 16 Tikkanen MJ, Nikkila EA, Kuusi T, Sipinen S. Different effects of two progestins on plasma high density lipoproteins (HDL2) and postheparin plasma hepatic lipase activity. Atherosclerosis 1981; 40: 365-369
    CrossrefPubMedGoogle Scholar